Asuragen this week announced that it will begin marketing early next month a microRNA diagnostic assay designed to differentiate pancreatitis from pancreatic ductal adenocarcinoma, making the company the first to commercialize a test based on the small, non-coding RNAs.
However, whatever edge the product launch may give Asuragen in the miRNA diagnostic market is likely to be short-lived since its two chief rivals, Rosetta Genomics and Ex
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
